ALCOHOL MISUSE, LIVER-GUT LINK

Saturday, June 16, San Diego, California, USA

Organizer: Manuela G. Neuman M.Sc., Ph.D., FCACB
manuela.neuman@utoronto.ca

This satellite is dedicated to Charles S. Lieber who was one of the pioneers of research in alcohol induced liver and gastro-intestinal injury. Clinical, translational and basic research on alcoholic and non-alcoholic hepatitis as well as a systematic review of drugs of misuse interactions will be covered.

This symposium will focus on the relationship between alcohol intake, and novel investigations on the risk for chronic diseases such as alcoholic and non-alcoholic steatohepatitis leading to liver cirrhosis and hepatocellular carcinoma. Knowing the interactions between alcohol and drugs of use and misuse is a new important task of scientific and medical community.

We strongly encourage participants with different research interests to interact, thus providing a platform for researchers to discuss their clinical and basic research ideas with this assembly of international experts.

The intention is to advance the international profile of RSA ANUAL SCIENTIFIC MEETING, both in terms of faculty and student participation. We also wish to further our mission of leading the forum to progress the science and practice of research in alcoholism. We would greatly appreciate your participation in this symposium.

This symposium is free of charge and will ensure a friendly and enjoyable atmosphere. Program Schedule is below. If you require more information about our symposium, please contact Manuela Neuman at: m_neuman@rogers.com.

TO RSVP: Contact Pamela Marett at rsastaff@sbcglobal.net

Manuela Neuman M.Sc., Ph.D., FCACC
Prof. Pharmacology and Toxicology, University of Toronto
CEO In Vitro Drug Safety and Biotechnology
Banting Institute, 100 College St., lab 217, M5G 0A5
Toronto, Ontario, Canada; Tel: 416-398 4880
manuela.neuman@utoronto.ca
9:00  Charles Lieber's Legacy - Manuela Neuman Ph.D.

9:15  The role of epigenetics, cancer stem cells and FAT10 driven tumorigenesis plays in the pathogenesis of HCC in ASH and NASH. Sam French MD, Harbor - UCLA Medical Center, Torrance, CA, USA.

9:40  CYP2E1-Inhibition as a therapeutic approach in non-cirrhotic alcoholic liver disease patients. Should it or does it work? Helmut Seitz, MD, Centre of Alcohol Research, University of Heidelberg, Heidelberg, Germany

10:10  Alcohol, acetylation and lipids. Pamela Tuma Ph.D., Department of Biology, The Catholic University of America, Washington DC., USA

10:30  Coffee break

10:45  Microbiota as therapeutic targets for alcoholic liver disease. Bernd Schnabl, MD University of California, San Diego, CA, USA

11:05  Microbiome and non-alcoholic fatty liver disease. Steve Malnick, Kaplan Medicak Centre, Hebrew University, Rehovot, Israel.

11:40  Molecular imaging diagnosis of early stage alcoholic liver fibrosis. Qi Cao MD. Ph.D, Diagnostic Radiology & Nuclear Medicine, University of Maryland Medical Center, MD, USA

12:00  Suicide prevention task force on alcohol, substance abuse & suicidality. Frederic Hellman, MD., Forensic Pathology Department, Ministry of Justice, Pennsylvania, USA

12:25  Interactions Alcohol Cannabis. Manuela Neuman Ph.D., In Vitro Drug Safety and Biotechnology, Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

12:45  Alcohol metabolism and its consequences. Samir Zakhari Ph.D., The Spirits of America, Washington, DC, USA

13:05  Impaired protein and lipid trafficking in the alcoholic fatty liver Carol A Casey, PhD, University of Nebraska Medical Center; The Liver Study Unit, Department of Internal Medicine, Department of Veterans Affairs Medical Center Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA.

13:25  Discussant and conclusion Kathy Jung Ph.D., Head of the Digestive Metabolism Section at NIAAA, Washington DC., USA